Global Lung Cancer Diagnostics Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 2.97 Billion |
 Market Size (Forecast Year) |
USD 8.59 Billion |
 CAGR |
% |
| Major Markets Players |
全球肺癌诊断市场，按产品类型（仪器、消耗品和配件）、测试类型（生物标志物测试、影像测试、活检、血液测试等）、癌症类型（非小细胞肺癌、小细胞肺癌）、最终用户（医院、相关实验室、独立诊断实验室、诊断影像中心、癌症研究机构等）、分销渠道（直接招标、零售销售）划分 - 行业趋势和预测到 2031 年。
肺癌诊断市场分析及规模
早期检测是肺癌诊断市场的主要特点，能够在治疗干预最有效的初期阶段识别肺癌。通过先进的筛查计划和诊断测试（如低剂量 CT 扫描和分子检测），医疗保健提供者可以在高风险人群或出现早期症状的人群中检测出肺癌。早期检测通过及时启动治疗来改善患者的治疗效果，并降低与晚期疾病管理相关的医疗成本。
例如，
根据美国国家生物技术信息中心 (NCBI) 的数据，早期非小细胞肺癌 (NSCLC) 的手术切除可使 5 年生存率高达 70%。然而，大多数患者被诊断为晚期疾病，尽管肿瘤治疗取得了进展，但生存率仍然很低。NCBI 的一份报告重点介绍了英国的统计数据，显示 I 期 (81-85%) 和 IV 期 (15-19%) 肺癌患者的 1 年生存率存在明显差异，强调迫切需要改进早期检测策略，以改善患者治疗效果并降低死亡率。
2023 年全球肺癌诊断市场规模价值 29.7 亿美元，预计到 2031 年将达到 85.9 亿美元，2024 年至 2031 年预测期内的复合年增长率为 14.2%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
肺癌诊断市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2024-2031 |
|
基准年 |
2023 |
|
历史岁月 |
2022 (可定制为 2016-2021) |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
产品类型（仪器、耗材及配件）、检测类型（生物标志物检测、影像检测、活检、血液检测等）、癌症类型（非小细胞肺癌、小细胞肺癌）、最终用户（医院、相关实验室、独立诊断实验室、诊断影像中心、癌症研究机构等）、分销渠道（直接招标、零售） |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. HoffmannLa Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), Quest Diagnostics Incorporated (U.S.), Biodesix (U.S.), Amoy Diagnostics Co., Ltd. (China), BioRad Laboratories, Inc. (U.S.), Biocartis (Belgium), Boditech Med Inc. (South Korea), Danaher (U.S.), Vela Diagnostics (Singapore), DiaSorin S.p.A. (Italy), Exact Sciences UK, Ltd. (U.K.), Guardant Health (U.S.), LalPathLabs (India), LungLife AI, Inc. (U.S.), MedGenome (India), Myriad Genetics, Inc. (U.S.), NeoGenomics Laboratories (U.S.), NanoString Technology (U.S.), Nanoentek (South Korea), Oncocyte Corporation (U.S.), PlexBio Co. Ltd. (Taiwan), QIAGEN (Germany), Siemens Healthcare GmbH (Germany), Veracyte, Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
Lung cancer is a malignant tumor that originates in the cells of the lungs, typically in the lining of the bronchi or the alveoli. It is primarily caused by long-term exposure to substances such as cigarette smoke, asbestos, and air pollution. Lung cancer is categorized into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), each with distinct characteristics and treatment approaches. Symptoms may include persistent cough, chest pain, shortness of breath, coughing up blood, and unexplained weight loss. Lung cancer is one of the most common cancers worldwide and a leading cause of cancer-related mortality.
Lung Cancer Diagnostics Market Dynamics
Drivers
- Growing Technological Advancements Enhances Reliability of Diagnostic Methods
Innovations in imaging technologies, such as computed tomography (CT) scans and positron emission tomography (PET) scans, enable early detection of lung nodules and metastases. Advancements in molecular diagnostics, including next-generation sequencing (NGS) and liquid biopsy techniques, facilitate the identification of specific genetic mutations and biomarkers associated with lung cancer. These technological breakthroughs improve diagnostic accuracy and enable personalized treatment strategies tailored to individual patients, thereby driving the demand for advanced diagnostic tools and services in the lung cancer diagnostics market.
For Instance,
In October 2023, DELFI Diagnostics' launch of FirstLook Lung represents a significant advancement in lung cancer diagnostics. While introducing a routine blood test for lung cancer screening, FirstLook Lung offers a non-invasive and accessible method for early detection. This innovative technology utilizes molecular diagnostics and biomarker analysis to enhance the accuracy of screening, aligning with the trend of technological advancements driving the lung cancer diagnostics market. The availability of such a convenient and precise screening tool improves early detection rates and underscores the importance of leveraging cutting-edge technologies to combat lung cancer effectively.
- Growing Awareness of Early Detection and Screening for Lung Cancer Leads to Better Disease Management
As public education campaigns raise awareness about risk factors such as smoking and environmental pollutants, individuals are more expected to seek preventive healthcare measures, including regular screenings. Advocacy efforts by healthcare organizations and patient groups further amplify awareness, prompting healthcare providers to prioritize lung cancer screening and diagnosis in their practice. Growing awareness plays a pivotal role in driving the uptake of lung cancer diagnostics, ultimately contributing to better disease management and reduced mortality rates.
Opportunities
- Rising Aging Population Leads to Growing Demand of Specialized Diagnostic Solutions
As people age, their risk of developing lung cancer increases, driving the demand for diagnostic tests and screening programs tailored to this demographic. Additionally, older adults often experience comorbidities and may have unique healthcare needs, necessitating comprehensive diagnostic approaches that consider age-related factors. The growing aging population in many regions, particularly in developed countries, creates a steady demand for lung cancer diagnostics, offering opportunities for market expansion and the development of specialized diagnostic solutions targeting this demographic.
- Increasing Investments in Research and Development promotes the Demand for Scalable Screening Programs
Research and development investments fuel innovation, leading to the development of advanced diagnostic technologies and novel biomarkers for early detection and accurate diagnosis of lung cancer. As R&D efforts progress, there is potential for the introduction of more cost-effective and efficient diagnostic solutions, addressing the growing demand for accessible and scalable screening programs. Furthermore, collaborations between academia, industry, and government entities foster interdisciplinary approaches, accelerating the translation of research findings into clinical applications. Ultimately, these investments pave the way for improved patient outcomes, reduced healthcare burden, and enhanced strategies for combating lung cancer globally.
Restraints/Challenges
- High Costs Associated with Lung Cancer Diagnostics limits Diagnostic Procedures
Advanced diagnostic techniques such as molecular testing and imaging modalities can be expensive, placing financial burdens on patients and healthcare systems asuch as. These costs may deter individuals from seeking timely screenings or diagnostic tests, resulting in delayed diagnosis and poorer outcomes. Additionally, limited reimbursement coverage for certain diagnostic procedures further exacerbates the affordability issue, particularly for uninsured or underinsured populations.
- Stringent Regulatory Approval Delays Introduction of Innovative Diagnostic Solutions
The approval process poses a significant restraint on the lung cancer diagnostics market. Developing and commercializing new diagnostic tests and technologies for lung cancer requires extensive clinical validation and regulatory clearance, which can be time-consuming and resource-intensive. Delays in obtaining regulatory approval prolong the time to market entry, hindering the introduction of innovative diagnostic solutions. Moreover, the complexity of regulatory requirements may deter smaller companies with limited resources from pursuing development efforts, limiting the diversity and competitiveness of the market.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global laboratory information management systems (LIMS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In August 2022, F. Hoffmann-La Roche Ltd. launched the Digital LightCycler System, a cutting-edge digital PCR system aiding clinical researchers in comprehending cancer, genetic diseases, and infections. This system enhances DNA and RNA analysis precision, specifically tailored for oncology and infectious disease laboratories
- In October 2022, Quest Diagnostics embarking on a renewed collaboration with Decode Health, marking a new phase in their partnership. This endeavor has streamlined the development of diagnostic tests and identification of novel medication targets for diverse cancers, while also bolstering Quest Diagnostics' global footprint
Lung Cancer Diagnostics Market Scope
The market is segmented on the basis of product type, test type, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables and Accessories
Test Type
- Biomarkers Tests
- Imaging Test
- Biopsy
- Blood Test
- Others
Cancer Type
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
End User
- Hospital
- Associated Labs
- Independent Diagnostic Laboratories
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Others
Distribution Channel
- Direct Tender
- Retail Sales
Lung Cancer Diagnostics Market Regional Analysis/Insights
The market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, end user, and distribution channel, as referenced above.
Some countries covered in the market are the U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan and Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Oman, Bahrain, Qatar, Kuwait and Rest of Middle East and Africa.
In North America, U.S. dominates in the market is anticipated due to a significant rise in awareness regarding early cancer detection and the importance of consultancy services. This heightened awareness has led to increased demand for advanced diagnostic technologies and services, driving market growth. Additionally, the U.S. boasts a robust healthcare infrastructure and a strong emphasis on research and development, further contributing to its leading position in cancer diagnostics. These factors collectively position the U.S. as a key player in shaping the future landscape of cancer diagnostics in North America.
In Europe, Germany is expected for growth in the lung cancer diagnostics market, driven by advancements in technology and the reliability of healthcare services. Germany's healthcare sector is renowned for its high standards and efficiency, which has instilled trust among patients and contributed to the adoption of diagnostic innovations. Additionally, the integration of healthcare data with portable devices enables personalized care and remote monitoring, enhancing diagnostic capabilities.
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
医疗保健基础设施增长安装基础和新技术渗透
该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。
竞争格局和肺癌诊断市场分析
市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
市场上的一些主要参与者包括：
- F. HoffmannLa Roche Ltd.（瑞士）
- 赛默飞世尔科技公司（美国）
- 雅培（美国）
- Quest Diagnostics Incorporated（美国）
- Biodesix（美国）
- 厦门诊断技术股份有限公司 (中国)
- BioRad Laboratories, Inc.（美国）
- Biocartis（比利时）
- Boditech Med Inc.（韩国）
- 丹纳赫（美国）
- Vela Diagnostics（新加坡）
- DiaSorin SpA（意大利）
- Exact Sciences UK, Ltd.（英国）
- Guardant Health（美国）
- LalPathLabs.com（印度）
- LungLife AI, Inc.（美国）
- MedGenome（印度）
- Myriad Genetics, Inc.（美国）
- NeoGenomics 实验室（美国）
- NanoString 技术（美国）
- Nanoentek（韩国）
- Oncocyte 公司 (美国)
- PlexBio 股份有限公司 (台湾)
- QIAGEN（德国）
- 西门子医疗有限公司（德国）
- Veracyte, Inc.（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
